The purpose of this study is to evaluate the safety of administration and effects of valproic
acid on clusterin expression in cognitively-intact, healthy, elderly subjects. Clusterin
mutations have recently been identified as a risk factor for the development of Alzheimer's
Disease and changes in clusterin expression are seen in the elderly who develop Alzheimer's
disease irrespective of whether they carry these genetic mutations or not. Valproic acid may
prevent or reverse these changes.
Fourteen subjects with normal memory and thinking will participate in this study. Ten of
these subjects will receive valproic acid and 4 will receive a "placebo" capsule with no
active medicine. Participants will take study medication or placebo for 28 days and be
followed for a total 35 days in this trial.